Turnstone Biologics Corp. (NASDAQ:TSBX) Short Interest Update

Turnstone Biologics Corp. (NASDAQ:TSBX) was the recipient of a large growth in short interest during the month of November. As of November 15th, there was short interest totalling 702,900 shares, a growth of 91.4% from the October 31st total of 367,200 shares. Approximately 5.2% of the shares of the company are sold short. Based on an average daily trading volume, of 283,300 shares, the days-to-cover ratio is presently 2.5 days.

Institutional Trading of Turnstone Biologics

An institutional investor recently bought a new position in Turnstone Biologics stock. Sei Investments Co. acquired a new position in shares of Turnstone Biologics Corp. (NASDAQ:TSBX) in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 11,882 shares of the company’s stock, valued at approximately $31,000. Sei Investments Co. owned about 0.05% of Turnstone Biologics as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 52.51% of the company’s stock.

Analyst Ratings Changes

Several research analysts have weighed in on TSBX shares. Bank of America downgraded Turnstone Biologics from a “neutral” rating to an “underperform” rating in a research note on Friday, November 15th. Piper Sandler lowered their target price on Turnstone Biologics from $20.00 to $3.75 and set an “overweight” rating on the stock in a research note on Monday, August 19th.

Turnstone Biologics Price Performance

Shares of TSBX stock traded up $0.01 during midday trading on Friday, hitting $0.52. The company had a trading volume of 22,303 shares, compared to its average volume of 225,742. The company’s 50 day simple moving average is $0.51 and its 200 day simple moving average is $1.52. Turnstone Biologics has a 52-week low of $0.44 and a 52-week high of $5.75. The stock has a market cap of $11.91 million, a price-to-earnings ratio of -0.16 and a beta of 2.21.

Turnstone Biologics (NASDAQ:TSBX) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.74) EPS for the quarter, beating the consensus estimate of ($0.87) by $0.13. Analysts anticipate that Turnstone Biologics will post -3.75 EPS for the current year.

Turnstone Biologics Company Profile

Turnstone Biologics Corp., a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. The company's lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, head and neck cancer and uveal melanoma, as well as an investigator sponsored trials to treat colorectal cancer, head and neck cancer, and cutaneous and non-cutaneous melanomas.